Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Boosted by Natixis Advisors LLC

Natixis Advisors LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 71,382 shares of the medical equipment provider’s stock after buying an additional 7,731 shares during the quarter. Natixis Advisors LLC’s holdings in Zimmer Biomet were worth $7,540,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $25,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet during the third quarter valued at approximately $35,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $39,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of analyst reports. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus lifted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Finally, Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $111.72 on Friday. The stock’s 50-day simple moving average is $106.62 and its 200-day simple moving average is $106.96. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a market capitalization of $22.24 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 1.95 and a beta of 1.04. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.